Design of a phase 3, randomized, double-blind, placebo-controlled, 48-week study to evaluate the efficacy and safety of cendakimab in adult and adolescent patients with eosinophilic esophagitis
Titel:
Design of a phase 3, randomized, double-blind, placebo-controlled, 48-week study to evaluate the efficacy and safety of cendakimab in adult and adolescent patients with eosinophilic esophagitis
Auteur:
Charriez, Christina M. Zhang, Sandra de Oliveira, Claudia H.M.C. Patel, Vrunda Oh, Young S. Hirano, Ikuo Schoepfer, Alain Dellon, Evan S.